These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31534084)

  • 41. Prescribing direct-acting antivirals to treat hepatitis C virus in a general practice setting in Australia: 'so why not do it'?
    Heard E; Massi L; Smirnov A; Selvey LA
    Intern Med J; 2020 Sep; 50(9):1053-1058. PubMed ID: 31589351
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
    Patel SV; Jayaweera DT; Althoff KN; Eron JJ; Radtchenko J; Mills A; Moyle G; Santiago S; Sax PE; Gillman J; Mounzer K; Elion RA; Huhn GD
    PLoS One; 2020; 15(2):e0228847. PubMed ID: 32053682
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system.
    Lam JO; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ; Marcus JL
    Int J STD AIDS; 2019 Jun; 30(7):689-695. PubMed ID: 31046611
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019.
    Reau N; Sulkowski MS; Thomas E; Sundaram V; Xu Q; Cheng WH; Marx SE; Hayes OA; Manthena SR; Chirikov V; Dylla DE; Brooks H; Carabino JM; Saab S
    Adv Ther; 2021 Dec; 38(12):5777-5790. PubMed ID: 34704194
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV-coinfected patients with mixed cryoglobulinaemia.
    Miailhes P; Hartig-Lavie K; Virlogeux V; Pradat P; Diakite M; Uhres AC; Zoulim F; Sarda MN
    Clin Microbiol Infect; 2018 Nov; 24(11):1215.e1-1215.e4. PubMed ID: 29870852
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: Data from a national US cohort.
    Serper M; Forde KA; Kaplan DE
    J Viral Hepat; 2018 Feb; 25(2):187-197. PubMed ID: 28845882
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy.
    Sagnelli E; Stroffolini T; Sagnelli C; Cacopardo B; Andriulli A; Babudieri S; Coppola N; Gaeta GB; Almasio PL
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):676-681. PubMed ID: 29465473
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.
    d'Arminio Monforte A; Cozzi-Lepri A; Ceccherini-Silberstein F; De Luca A; Lo Caputo S; Castagna A; Mussini C; Cingolani A; Tavelli A; Shanyinde M; Gori A; Girardi E; Andreoni M; Antinori A; Puoti M;
    PLoS One; 2017; 12(5):e0177402. PubMed ID: 28520749
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vital Signs: Hepatitis C Treatment Among Insured Adults - United States, 2019-2020.
    Thompson WW; Symum H; Sandul A; ; Gupta N; Patel P; Nelson N; Mermin J; Wester C
    MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(32):1011-1017. PubMed ID: 35951484
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased peripheral CD4
    Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
    J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada.
    Kronfli N; Nitulescu R; Cox J; Moodie EE; Wong A; Cooper C; Gill J; Walmsley S; Martel-Laferrière V; Hull MW; Klein MB;
    J Int AIDS Soc; 2018 Nov; 21(11):e25197. PubMed ID: 30460791
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care centre: Results of the Telepass project.
    Ponziani FR; Santopaolo F; Siciliano M; De Belvis AG; Tortora A; Mora V; Fanali C; Morsella A; Balducci F; Vetrugno G; D'Alfonso ME; Cambieri A; Cauda R; Bellantone R; Sanguinetti M; Pompili M; Gasbarrini A
    J Viral Hepat; 2021 Apr; 28(4):651-656. PubMed ID: 33421220
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs.
    Socías ME; Ti L; Dong H; Shoveller J; Kerr T; Montaner J; Milloy MJ
    HIV Med; 2017 Oct; 18(9):647-654. PubMed ID: 28294492
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Road to Hepatitis C Virus Cure: Practical Considerations from a Health System's Perspective.
    Jonas MC; Loftus B; Horberg MA
    Infect Dis Clin North Am; 2018 Jun; 32(2):481-493. PubMed ID: 29778267
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy.
    Virlogeux V; Berthillon P; Bordes I; Larrat S; Crouy S; Scholtès C; Pradat P; Maynard M; Zoulim F; Leroy V; Chemin I; Trépo C; Petit MA
    Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):313-318. PubMed ID: 29551607
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study.
    Arora SS; Axley P; Ahmed Z; Satapathy SK; Wong R; Kuo YF; Singal AK
    Transpl Int; 2019 Aug; 32(8):854-864. PubMed ID: 30866110
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients.
    Yaya I; Roux P; Marcellin F; Wittkop L; Esterle L; Spire B; Dominguez S; Elegbe BA; Piroth L; Sogni P; Salmon-Ceron D; Carrieri MP;
    PLoS One; 2018; 13(7):e0199874. PubMed ID: 29975764
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit.
    Selvapatt N; Ward T; Harrison L; Lombardini J; Thursz M; McEwan P; Brown A
    Liver Int; 2017 Mar; 37(3):345-353. PubMed ID: 27566283
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Elimination of Hepatitis C Virus in Australia: Laying the Foundation.
    Dore GJ; Hajarizadeh B
    Infect Dis Clin North Am; 2018 Jun; 32(2):269-279. PubMed ID: 29778255
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Current management of hepatitis C].
    Lange CM
    Med Monatsschr Pharm; 2015 Sep; 38(9):337-44; quiz 345-6. PubMed ID: 26731851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.